O
EVMN

OrbiMed’s Evommune Inc EVMN Stock Holding History

OrbiMed’s Portfolio EVMN Stock Details EVMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.14M Buy
+161,000
New +$3.74M 0.04% 122

Other funds holding EVMN

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

OrbiMed's EVMN Position: Q2 2026 in Review

OrbiMed opened a new position in Evommune Inc (EVMN) in Q2 2026: 161,000 shares worth $2.14M. The stake represents 0.04% of the portfolio and ranks #122 among its holdings.

105 funds tracked by Wall St. Rank hold EVMN as of Q2 2026.

  • OrbiMed held 161,000 shares of Evommune Inc worth $2.14M as of Q2 2026.
  • Evommune Inc was a new OrbiMed position in Q2 2026.
  • Evommune Inc made up 0.04% of OrbiMed's portfolio in Q2 2026, its #122 holding.
  • 105 funds tracked by Wall St. Rank held Evommune Inc as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.